Pyrimidine-containing Heterocyclic Anticancer Agents: Systematic Development, SAR, and Mechanistic Pathways

Cancer remains one of the most prominent causes of death, affecting millions of lives globally, thereby posing a significant disease burden. Heterocyclic scaffolds, particularly pyrimidines, have proven effective owing to their versatile activity across various cancer types. This review aims to provide an extensive compilation of pyrimidine-based hybrid molecules as promising anti-proliferative agents, highlighting their synthesis, multi-target capabilities, key signaling pathways, structure-activity relationships (SARs), molecular targets, and therapeutic potential against cancer cells.

A comprehensive literature survey was conducted using PubMed, Elsevier, Google Scholar, ScienceDirect, ACS, RSC, and PubChem to identify relevant reviews and research articles published between 2020 and 2025. The collective study was analyzed to evaluate pyrimidine-based hybrid structural modification, molecular targets, anticancer mechanism, and pharmacological properties.

Pyrimidine-based hybrid molecules have demonstrated antiproliferative activity, with several derivatives demonstrating excellent inhibitory potency, enhanced target selectivity, and improved pharmacokinetic characteristics. Pyrimidine hybrids effectively modulate multiple oncogenic targets and signaling pathways, including PI3K/AKT, CDKs, EGFR, HSP90a, and HDAC, leading to cell cycle arrest and apoptosis and inhibiting tumor growth. Further SAR revealed that strategic substitution on the pyrimidine scaffold significantly increased bioavailability, reduced toxicity, and improved target selectivity.

The literature indicates that pyrimidine-based hybrid molecules have significant potential as multitargeted anticancer agents, addressing the limitations of conventional single-target therapies. Their structural diversity was shown to modulate multiple cancer-related signaling pathways. The study highlights their promising, valuable lead scaffold for the development of next-generation anticancer agents.

Pyrimidine-containing hybrids emerge as a privileged scaffold in medicinal chemistry for the development of effective, multitargeted anticancer agents with improved pharmacological profiles and reduced off-target effects. Therefore, further structural optimization and mechanistic analysis, along with preclinical evaluation, suggest that pyrimidine-based molecules hold significant promise for cancer therapy.